Literature DB >> 7631637

Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns.

O S Levine1, D Vlahov, J Koehler, S Cohn, A M Spronk, K E Nelson.   

Abstract

To investigate the epidemiology of hepatitis B virus (HBV) infection among injecting drug users, the authors assessed the prevalence of HBV seromarkers among 2,558 injecting drug users recruited through street outreach in Baltimore, Maryland, in 1988-1989. Eighty percent of the drug users had at least one HBV seromarker. HBV seropositivity was associated with increasing age, duration of injecting drug use, African-American ethnicity, injecting drugs at least once daily, and sharing needles or visiting "shooting galleries" during the previous 11 years, but not with high-risk sexual behaviors or a history of sexually transmitted disease. This finding is possibly due to the relative inefficiency of sexual transmission as compared with parenteral transmission in injecting drug users. In addition, HBV seropositivity was strongly associated with seropositivity for hepatitis C virus and human immunodeficiency virus. The authors conclude that HBV transmission among injecting drug users occurs primarily through the sharing of contaminated drug injecting equipment rather than through sexual relations, and that efforts to prevent HBV infection must target injecting drug users early in their injecting careers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7631637     DOI: 10.1093/oxfordjournals.aje.a117639

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  24 in total

1.  Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users.

Authors:  Thanh Q Tran; Carolyn Z Grimes; Dejian Lai; Catherine L Troisi; Lu-Yu Hwang
Journal:  Vaccine       Date:  2011-11-08       Impact factor: 3.641

2.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

3.  Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.

Authors:  P Sadaphal; J Astemborski; N M Graham; L Sheely; M Bonds; A Madison; D Vlahov; D L Thomas; T R Sterling
Journal:  Clin Infect Dis       Date:  2001-10-12       Impact factor: 9.079

4.  Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.

Authors:  David Widjaja; Suresh Yarlagadda; Bheema S Singu; Raghu S Loganathan; Steve Blum; Alan Bloom; Prospere Remy
Journal:  J Natl Med Assoc       Date:  2007-04       Impact factor: 1.798

5.  Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.

Authors:  R S Garfein; D Vlahov; N Galai; M C Doherty; K E Nelson
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

Review 6.  Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users.

Authors:  Antonio L Estrada
Journal:  Public Health Rep       Date:  2002       Impact factor: 2.792

7.  Predictors of syphilis seroreactivity and prevalence of HIV among street recruited injection drug users in Los Angeles County, 1994-6.

Authors:  J López-Zetina; W Ford; M Weber; S Barna; T Woerhle; P Kerndt; E Monterroso
Journal:  Sex Transm Infect       Date:  2000-12       Impact factor: 3.519

8.  Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis.

Authors:  Cassidy W Claassen; Marie Diener-West; Shruti H Mehta; David L Thomas; Gregory D Kirk
Journal:  Clin Infect Dis       Date:  2012-03-28       Impact factor: 9.079

9.  GBV-C RNA presence in several high-risk groups of Spain.

Authors:  E Quirós; G Piédrola; M C Maroto
Journal:  Eur J Epidemiol       Date:  1998-09       Impact factor: 8.082

10.  Economic evaluation of delivering hepatitis B vaccine to injection drug users.

Authors:  Yiqing Hu; Lauretta E Grau; Greg Scott; Karen H Seal; Patricia A Marshall; Merrill Singer; Robert Heimer
Journal:  Am J Prev Med       Date:  2008-07       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.